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ABSTRACT:  Clarithromycin is a new macrolide that has a longer half-life than
erythromycin and is claimed to reach higher tissue concentrations.  We aimed to
investigate whether, following oral administration, the drug and its 14-hydroxy
metabolite reach levels in lung tissue that are likely to be clinically effective against
common respiratory pathogens.
Ten patients undergoing diagnostic bronchoscopy received seven doses of clar-
ithromycin, 500 mg b.i.d. orally.  Bronchoscopy was performed at a mean time of
4.25 h after the last dose.  At bronchoscopy, bronchial biopsies and bronchoalveo-
lar lavage were performed.  Clarithromycin and its 14-OH metabolite were mea-
sured in serum, bronchial biopsies, epithelial lining fluid (ELF) and alveolar cells.
Mean levels of clarithromycin were 4.0 mg·l-1 in serum, 16.8 mg·kg in bronchial
biopsies, 20.5 mg·l-1 in ELF and 372.7 mg·l-1 in alveolar cells.  The equivalent lev-
els of 14-OH metabolite were 0.7, 2.7, 1.9 and 38.6 mg·l-1, respectively.
We conclude that there is considerable concentration of clarithromycin and its
14-OH metabolite in alveolar cells, and to a lesser extent in bronchial tissue and
ELF; this implies efficacy against susceptible organisms at these sites.
Eur Respir J., 1994, 7, 1275–1280.
Depts of *Thoracic Medicine, and +Medical
Microbiology, Dudley Road Hospital,
Birmingham, UK. **Dept of Pharmacology,
University of Regensburg, Regensburg,
Germany.
Correspondence:  D. Honeybourne 
Dept of Thoracic Medicine
Dudley Road Hospital
Birmingham B18 7QH
UK.
Keywords:  Bronchial mucosa
clarithromycin
epithelial lining fluid
macrophages
Received: April 4 1993
Accepted after revision January 26 1994
The efficacy of erythromycin has been limited by  poor
gastrointestinal absorption and gastrointestinal side-
effects.  In addition, marginal activity against Haemophilus
influenzae limits the use of erythromycin alone in lower
respiratory tract infection.
Clarithromycin is the 6-0-methyl derivative of erythrom-
ycin.  Unlike erythromycin, acid catalysed cyclization
to specific anhydro-hemiketal and spiroketal derivatives
does not occur;  therefore, clarithromycin  has much  greater
acid stability than erythromycin [1].  In humans, clar-
ithromycin has at least four active metabolites, the most
active being the 14-hydroxy compound.  This is in marked
contrast to some animal models, e.g. mice, which do not
produce 14-hydroxy metabolites [2].  There is some evi-
dence to suggest a possible synergy between clarithro-
mycin and its 14-hydroxy metabolite, which may be of
relevance for some infections [3].  Clarithromycin serum
half-life is longer than erythromycin, and some studies
have suggested tissue concentrations to be higher after
oral clarithromycin than after oral erythromycin [4].
Macrolides are known to accumulate within cells, includ-
ing neutrophils and macrophages [5].
This study was designed to look at the potential accu-
mulation of clarithromycin and its 14-hydroxy metabo-
lite in human bronchial mucosa, and by performing
bronchoalveolar lavage (BAL) to measure the content
in epithelial lining fluid and alveolar cells.  Epith-
elial lining fluid is that fluid which lines the airspace
distal to the point of wedge of the bronchoscope, and is
recovered by BAL.  Clarithromycin has a wide range of
activity against many respiratory pathogens, and this
study investigates whether the drug and its 14-hydroxy
metabolite reach levels in lung tissue that are likely
to be clinically effective against these respiratory path-
ogens.
Patients and Methods
Patients
Ten patients (9 male) who were undergoing fibre-
optic bronchoscopy for diagnostic purposes were ad-
ministered oral clarithromycin, 500 mg b.i.d., for three
days and then a single dose of 500 mg on the morning
of bronchoscopy.  This last dose was administered bet-
ween 2.5–5.5 h before bronchoscopy.  Subjects had a
mean age of 65 yrs (range 37–78 yrs).  The underlying
diagnoses were carcinoma of the lung in seven patients,
haemoptyses of unknown cause in two patients and focal
fibrosis in one patient.  Exclusion criteria were the
presence of active pulmonary infection, a history of
allergy to macrolides, administration of antimicrobial
agents in the previous two weeks, significant hepatic or
renal impairment, and women of child-bearing potential.
Subjects were also excluded if they were taking med-
ications known to interact with macrolides.  All subjects
gave informed written consent and the study was approved
by the hospital Ethics Committee. 
Methods
Bronchoscopy was performed after premedication
with atropine, 0.6 mg i.m., nebulized 4% lignocaine, 160
mg, and midazolam, 2–7 mg i.v., just prior to bron-
choscopy.  After a careful examination of the airways,
a standard BAL was performed using isotonic saline
(divided into four 50 ml aliquots), with gentle aspir-
ation following instillation of each of the aliquots.
Lavage was performed in the right middle lobe, or if
this area had a macroscopically abnormal appearance
or was abnormal on chest X-ray then the lingula was
used.  The fluid recovered from the first 50 ml was
discarded in order to avoid contamination with proxi-
mal airway cells and secretions.  The maximum time taken
for complete lavage was 3 min.  Bronchial biopsies were
taken from macroscopically normal subcarinae, and a
blood sample was then taken for determination of the
simultaneous serum level of antibiotic.
Laboratory procedures
The lavage aspirate was immediately centrifuged at
400× g for 5 min, after a small aliquot had been removed
for total cell counts.  Immediate centrifugation was nec-
essary to minimize any diffusion of antibiotic from the
alveolar cells into the lavage fluid.  The lavage aspirate
was only processed if the differential cell count contained
at least 90% macrophages.  To avoid cell loss due to
adherence to surfaces, Teflon containers and siliconized
glassware were used.  The urea content of the super-
natant was measured with a modified Sigma diagnostic
kit (Sigma Chemicals, Poole, UK).  The blood urea con-
centration was measured from the blood sample taken at
bronchoscopy.  Antibiotic concentration in the epithelial
(alveolar) lining fluid was calculated using the urea dilu-
tion method [6]:
ELF antibiotic concentration = ACL X UB
UL 
where UL=urea concentration in the lavage; UB=urea
concentration of blood, and ACL=antibiotic concentra-
tion in the lavage.
Alveolar macrophage cell volume was measured using
velocity gradient centrifugation  [7].  The mean cell vol-
ume was 2.48 µl·10-6 cells (SEM 0.52).
The lavage supernatant was freeze-dried and then
resuspended in distilled water to yield a ten-fold con-
centration.  This, together with the cell pellet contain-
ing predominantly alveolar macrophages, was frozen
at -70°C.  Bronchial biopsies were collected in a humid-
ity chamber and any blood-stained samples were dis-
carded.  After weighing, the samples were stored at
-70°C before assay.  An improved Neubauer haemocy-
tometer was used to measure the total white cell count.
Assay of the clarithromycin and 14-hydroxy metabolite
was performed on serum, lavage supernatant, alveolar
macrophages and bronchial mucosa tissue, by high per-
formance liquid chromatography (HPLC).
HPLC analysis used a pump LKB 2248 with pulse
dampener (Pharmacia, Freiburg, Germany), auto-sampler
SIL-9A (Shimadzu Europe, Duisburg, Germany), col-
umn heater TCM 100 (30°C, Millipore-Waters Chro-
matography, Eschborn, Germany), electrochemical
detector (ESA Inc., Bedford, MA, USA) and integrator
C-R4A (Shimadzu Europe, Duisburg, Germany).   Separ-
ation was achieved using a Zorbax SB-CN column.
The mobile phase consisted of 450 ml of 50 mM
sodium dihydrogen phosphate, 300 ml acetonitrile and
50 ml methanol, adjusted to pH 7.3 with 10 N sodium
hydroxide.  Using a flow rate of 1 ml·min-1, the re-
tention times of the analyses were 7.7 min (ClaOH),
13.1 min (Clari) and 14.7 min (roxithromycin internal
standard).
To 500 µl serum were added: 100 µl water (standard:
100 µl water containing 1 µg Clari and 0.5 µg ClaOH),
and 100 µl internal standard solution (10 µg·ml-1 roxi-
thromycin in water).  The sample was mixed and then
deproteinized by addition of 500 µl acetonitrile.  Mix-
ing was followed by 20 min incubation at 4°C and cen-
trifugation.  The supernatant was diluted with 1 ml water
and transferred into a disposable column (Adsorbex,
filled with 100 mg C18 silicagel, Merck Co.; Darmstadt,
Germany), which had been equilibrated with 5 ml of
methanol followed by 2 ml of 50 MM sodium phos-
phate buffer (pH=6.3).  After the supernatant had passed
through the extraction column, it was washed twice
with 2.5 ml of 50 MM sodium phosphate buffer (pH=
6.3).  The compounds of interest were eluted with 1 ml
methanol, which was subsequently diluted with 1 ml of
water, and then 50 µl was injected into the analytical
column.
Bronchial biopsies (4–9 mg) were homogenized in a
Weaton micro-homogenizer with 20 volumes of 50 MM
sodium phosphate buffer, pH=7.0, containing 100 ng·ml-1
roxithromycin (internal standard).  For protein precipi-
tation, an equal volume of acetonitrile was added.  After
incubation at 4°C (15 min) and centrifugation (2 min at
10,500×g), 25 µl supernatant were injected onto the ana-
lytical column.
The alveolar cell suspension was diluted with water
to a final volume of 1,000 µl, ultrasonicated on ice for
1 min at 70% duty cycle (Branson Sonifier with micro-
tip), and centrifuged.  Five hundred microlitres super-
natant was further treated as for the serum.
Lavage fluid (5 ml) was spiked with 100 µl internal
standard (10 µg·ml-1 aqueous roxithromycin solution)
and pipetted into a disposable column (Adsorbex (R)
filled with 100 mg C.18 silicagel).  Further treatment
was as for serum samples.
A problem arose from high lignocaine concentrations
in bronchial lavage (up to 50 µg·ml-1), which, because
of similar retention characteristics, could interfere with
quantification of ClaOH, and which poisoned the detec-
tor cell (reducing the response of the detector).  Better
separation of lignocaine from ClaOH was achieved by
increasing the pH to 7.5–7.6 (ligno=5.8 min; ClaOH=9.3
min; Clari=16.1 min; Roxi=18.8 min).  The detector
response recovered with time after prolonged washing
with methanol.
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The assay was validated for plasma/serum and water.
Linearity was checked and proven from 0.1 µg·ml-1
(r>0.9996 for Clari, and r>0.997 for ClaOH).  The
limit of quantification was 50 ng·ml-1, the limit of de-
tection (signal to noise ratio 3:1) was 400 pg (Clari and
ClaOH) and 600 pg for Roxi.  The recovery of the ana-
lytes was 70–90%, the mean recovery was 87, 67 and
76% from serum, for Clari, ClaOH and Roxi respec-
tively, and 87, 87 and 95% from water/bronchial lav-
age, respectively. Quality control was performed by
assaying spiked samples with each run.  The precision
was 4–5% for Clari (conc. 0.26–4.2 µg·ml-1) and 6–10%
for ClaOH (conc. 0.11–1.8 µg·ml-1).
Results 
Table 1 shows the individual results of the clari-
thromycin and the 14-hydroxy metabolite in serum
bronchial mucosa, epithelial lining fluid and alve-
olar cells.  Concentration of clarithromycin and the 14-
hydroxy metabolite occurred in bronchial biopsies,
epithelial lining fluid and alveolar macrophages, when
compared to simultaneous serum levels.  The ratio of
clarithromycin to 14-hydroxy metabolite was around
6:1 in serum and also in bronchial mucosa, but in
the ELF was 15:1 and alveolar cells 9.6.  Table 2 shows
the ratio of clarithromycin to 14-hydroxy metabolite at
each site.  The ratio is similar in serum and bronchial
biopsies but higher in ELF and alveolar cells.  In two
patients interference occurred in the HPLC measurements
due to lignocaine contamination of the lavaged specimens.
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Table 1.  –  Site concentrations of clarithromycin and its 14-hydroxy metabolite
Pt       Time after        Serum           Serum         Biopsy        Biopsy           ELF          ELF      Macro        Macro
No.        dose           clarith.       14-hydrox.      clarith.  14-hydrox.      clarith. +   14-hydrox. clarith     14-hydrox.
h               mg·l-1 mg·l-1 mg·kg-1 mg·kg-1 mg·l-1 mg·l-1 mg·l-1 mg·l-1
1 4.32   3.58  0.901   23.7   4.59  *   *   533.2 46.4
2 5.23 2.69 1.05 13.4 3.71 * * 679.1 80.5
3 4.28 1.62 0.31 6.46 2.4 8.08 INT 407.0 INT
4 3.5 2.23 0.17 7.43 1.01 15.15 3.39 338.9 44.2
5 5.15 2.55 0.23 8.86 1.62 19.34 INT 315.0 29.1
6 4.5 0.97 0.28 4.55 2.03 8.55 1.51 126.3 20.5
7 5.5 2.45 0.39 6.83 1.18 0.67 0.04 203.9 19.5
8 3.77 11.3 1.39 38.5 3.01 51.3 1.6 503.0 33.6
9 3.33 1.6 0.38 7.76 1.22 12.2 0.6 248.2 35.1
10 2.95 10.6 1.74 50.1 5.86 48.4 4.3 – –
Mean 4.25 3.96 0.68 16.76 2.66 20.46 1.90 372.7         38.61
SEM 0.27 1.19 0.17 4.98 0.51 6.70 0.67 58.6          6.90
*: lavage not sent for assay;  INT: interfering peak on HPLVC:  Pt: patient;  –: insufficient sample;  ELF: epithelial lining fluid;
clarith: clarithromycin;  14-hydrox: 14-hydroxy metabolite;  Macro: macrophage;  HPLC: high performance liquid chromato-
graphy.
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Fig. 1.  –  Concentrations of clarithromycin at different sites accord-
ing to time after last dose.  ❏: alveolar cell clarithromycin (mg·l-1);
❍: serum clarithromycin (mg·l-1); ∆: biopsy clarithromycin (mg·l-1);
: epithelial lining fluid clarithromycin (mg·l-1). 
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Fig. 2.  –  Concentrations of 14-hydroxy clarithromycin at different
sites according to time after last dose.  ❏: alveolar cell 14-hydroxy
clarithromycin (mg·l-1); ❍: serum 14-hydroxy clarithromycin (mg·l-1);
∆: biopsy 14-hydroxy clarithromycin (mg·kg-1); : epithelial lining
fluid 14-hydroxy clarithromycin (mg·l-1).
Table 2.  –  Ratios of clarithromycin to 14-hydroxy metabolite
Serum      Bronchial      ELF         Alveolar
biopsy                        cells
Mean  6.41    6.00   15.09    9.63
SD 3.42   3.09   10.35   2.88
SEM 1.08    0.98    4.23    1.02
ELF: epithelial lining fluid.
In two patients, insufficient lavage fluid supernatant was
available for ELF calculation, and in one patient insuf-
ficient quantity of cell pellet was available for measure-
ment of alveolar cell levels.  The mean volume of aspirate
from the lavage procedure was 47.3 ml (SD 10.0), and
the mean apparent volume of ELF using the urea tech-
nique was 14.2 µl.
Figure 1 illustrates the spread of the clarithromycin
concentrations in the four sites according to time after
last dose, and figure 2 shows the 14-hydroxy levels. Both
figures show that a steady state of drug concentration
had been reached after the seven doses of clarithromycin.
Discussion
We found clarithromycin and the 14-hydroxy meta-
bolite to be concentrated in bronchial biopsies, ELF
and alveolar cells compared to serum levels.  In one
earlier study [8], the concentration of clarithromycin
reached a peak in various tissues, including whole lung,
4 h after oral administration of 500 mg b.i.d. for 3 days.
Our mean serum level of 4.0 mg·l-1 was slightly higher
than their mean serum level of 2.5 mg·l-1.  Steady-state
serum levels occurred after five doses of clarithromycin
[9]. Following clarithromycin, 500 mg b.i.d. for up to
3.5 days in healthy volunteers, mean plasma ranges
for clarithromycin were 2.4–3.5 mg·l-1 and for 14-OH
were 0.7–0.8 mg·l-1 [10, 11], values very similar to our
own.
This study has found high levels of clarithromycin
and 14-OH in bronchial mucosal tissue, and similar lev-
els in ELF.  The urea method [6] for measuring ELF
volume suffers from net movement of solute from pul-
monary capilaries into the alveolar space, resulting in an
underestimation of drug concentration.  Other techniques
for measuring ELF volume have technical difficulties,
e.g. blood contamination caused by trauma [12].  More
accurate techniques of ELF volume measurement are
being developed [13].  Extremely high levels of both
clarithromycin and 14-OH were thus found in alveolar
cells.  Like other macrolides, clarithromycin has been
found to be highly concentrated in human polymor-
phonuclear leucocytes [5, 14], but little information is
available about human alveolar macrophages.  At all
sites studied a steady-state has been reached after the
seven doses of clarithromycin.  The ratio of clarithro-
mycin to 14-OH was found to be similar in the bronchial
biopsies compared to serum, but higher in the ELF and
alveolar cells, suggesting differing abilities of the two
molecules in penetrating to these sites, or perhaps a differ-
ent rate of clearance.
Macrolides are lipid soluble and have a low degree
of ionization, and hence have good tissue penetrat-
ion [15].  Clarithromycin has been shown to achieve
higher levels than erythromycin in the lungs of rodents
[4].  Azithromycin [16] has also been found to be con-
centrated in lung tissues.  Roxithromycin, however, is
not concentrated in lung tissues to the same extent [8].
One study in humans showed levels of clarithromycin
of 17.5 mg·kg-1 in whole lung tissue with a serum level
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of 2.6 mg·l, but the study used a bioassay which would
not have differentiated between parent compound or
14-OH metabolite [18].  The major and most microbio-
logically active metabolite is 14-hydroxy-clarithro-
mycin [17].  Hydration of clarithromycin produces
stereo-isomers 14-(R) and 14(S).  The epimer with the
higher antibacterial effect is the 14-(R) form, which
is also the main circulating epimer.  The process of
14-hydroxylation is dose-dependent [18].
The levels of clarithromycin in the various potential
sites of pulmonary infection can be compared to re-
ported in vitro activity.  The minimal 50% and 90%
inhibitory concentration (MIC90) of clarithromycin and
14-hydroxy-clarithromycin are shown in Table 3.
The MIC50 of clarithromycin and 14-hydroxy-clari-
thromycin to Streptococcus pneumoniae are both
reported to be 0.12 mg·l-1; although some relatively  resis-
tant organisms have been found, with one study report-
ing a MIC90 of 16 mg·l-1 [19].   However, other workers
have found the MIC90 to be as low as 0.015 mg·l-1 [20,
21].  Our study used the relatively high dose of 500
mg b.i.d., which may be chosen for more severe infec-
tions.  The bronchial biopsy levels (mean 16.8 mg·kg-1)
of clarithromycin are, in general, likely to be adequate
in the context of bronchitis, although the 14-OH biopsy
level is less impressive.  Similarly, the mean ELF con-
centration of clarithromycin of 20.5 mg·l-1 suggests good
efficacy against the pneumococcus in pneumonia, al-
though the 14-OH level is much lower.  Our subjects
did not have active infection including either pneu-
monia or bronchitis, so the levels found may not nec-
essarily be the same in the presence of such infection.
Clarithromycin and 14-OH clarithromycin have both
been shown to be independently effective against pneu-
mococcal infection in a mouse model, and significantly
more effective than erythromycin [22].
Levels of clarithromycin and 14-OH are likely to be
adequate at all sites against Moraxella catarrhalis
(MIC90 0.06 mg·l-1).  Poor activity against Haemophilus
influenzae has been a major drawback in using erythro-
mycin.  In a murine model of H. influenzae infection,
the 14-OH-clarithromycin metabolite was found to be
effective [23].  Some workers have suggested in vitro
synergy of clarithromycin and 14-OH-clarithromycin
against H. influenzae [3, 24), although the relatively low
levels of 14-OH in ELF and mucosa in our study may
not support this occurrence in vivo. The low MIC90 (0.03
Table 3.  –  In vitro susceptibility to clarithromycin and
the 14-hydroxy metabolite (mg·l-1)
MIC50 MIC90
S. pneumoniae
Clarithromycin    0.02–0.12    0.02–16
14-hydroxy 0.02–0.12 0.02–16
H. influenzae
Clarithromycin 4 8
14-hydroxy 4 4
M. catarrhalis
Clarithromycin 0.06 0.06
14-hydroxy 0.06 0.12
Taken from [19–21].  MIC50, MIC90: minimal 50%/90% inhibito-
ry concentration.
mg·l-1) of clarithromycin against Mycoplasma pneumo-
niae [25] and against Legionella pneumophila (MIC90,
0.12 mg·l-1) [26] suggest high efficacy in these atypical
pneumonias.  Initial clinical studies in severe Legionella
pneumophila infection have been favourable [27].  Clari-
thromycin was also found to be highly active against
Chlamydia pneumoniae [28].
Activity of clarithromycin against Mycobacterium
avium complex (MAC) inside mouse cells and human
alveolar macrophages has been reported, and was
greater than erythromycin [29].  Improved efficacy of
clarithromycin has been reported against MAC when
combined with ethambutol and rifampicin [30].  The lat-
ter study incubated macrophages in a clarithromycin
concentration of 2 mg·l-1, i.e. slightly below the mean
serum level in our study.  The extremely high levels of
clarithromycin and 14-OH-clarithromycin within human
alveolar cells in our study suggest its use in MAC.  Clini-
cal studies of clarithromycin in MAC have shown effi-
cacy [31].
Ultimately, evidence of efficacy in respiratory infec-
tion relies on clinical studies.  A significantly higher
clinical cure rate for clarithromycin compared to ery-
thromycin stearate has been reported in community-
acquired pneumonia (CAP),  with a lower rate of adverse
effects in the clarithromycin group [32].  A high clini-
cal cure rate for clarithromycin used in acute bacterial
exacerbations of chronic bronchitis has also been report-
ed [33].  We conclude that there is considerable con-
centration of both clarithromycin and its 14-hydroxy
metabolite in alveolar cells, and to lesser extent in ELF
and bronchial tissue.
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